GI Symposium data underscores pelareorep's clinical benefit in anal and pancreatic cancers Pelareorep featured in Key Opinion ...

Incyte Corp.’s Zynyz (retifanlimab-dlwr) has received another U.S. FDA approval and put some distance between it and a 2021 ...

FDA-approved as the first and only approved first line treatment for advanced squamous cell carcinoma of the anal canal.

The FDA approved retifanlimab (Zynyz; Incyte) as the first and only first-line treatment for advanced anal cancer, supported ...

PD-1 antibody was approved as first-line treatment for locally recurrent or metastatic squamous cell anal carcinoma.

With two concurrent FDA approvals, Incyte’s PD-1 inhibitor Zynyz has redeemed itself in anal cancer four years after an ...

The FDA also approved the use of Zynyz as a monotherapy for patients with squamous cell carcinoma of the anal canal who are ...

Author Julia DeVillers was daignosed with anal cancer and as it progresses, she was told she had 48 hours to live. Her ...

Operator: Good afternoon, and welcome to Oncolytics Biotech First Quarter Conference Call. All participants are in a listen-only mode.

The FDA has approved Zynyz (retifanlimab-dlwr) to treat patients with squamous cell carcinoma of the anal canal.

Jim Ross is sharing an update on his challenging health journey. The WWE Hall of Famer revealed that he has been diagnosed ...

Retifanlimab-dlwr (Zynyz) has been granted approval from the FDA for treatment of locally recurrent or metastatic squamous ...